mebendazole has been researched along with Malignant Melanoma in 7 studies
Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.
mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| " the apoptosis as well as autophagy and their related signaling in several stabilized cell lines as well as human explant melanoma cells treated with flubendazole (FLU)." | 7.96 | An analysis of mitotic catastrophe induced cell responses in melanoma cells exposed to flubendazole. ( Rudolf, E; Rudolf, K, 2020) |
| " We find that MBZ synergizes with the MEK inhibitor trametinib to inhibit growth of BRAFWT-NRASQ61K melanoma cells in culture and in xenografts, and markedly decreased MEK and ERK phosphorylation." | 7.85 | The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma. ( Abdussamad, M; Atkins, MB; Byers, SW; Calvert, V; Chen, YS; Dakshanamurthy, S; Fang, HB; Gaur, A; Petricoin, EF; Rosenthal, DS; Simbulan-Rosenthal, CM; Zapas, J; Zhou, H, 2017) |
| "Mebendazole (MBZ) was identified as a promising therapeutic on the basis of its ability to induce apoptosis in melanoma cell lines through a B-cell lymphoma 2 (BCL2)-dependent mechanism." | 7.79 | XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. ( Byron, SA; Doudican, NA; Orlow, SJ; Pollock, PM, 2013) |
| "In recent years, treatment of melanoma and a range of other deadly cancers has involved immunotherapy with programmed cell death protein-1 (PD-1)/PD-1 ligand (PD-L1) checkpoint blockade which has improved survival." | 5.51 | The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation. ( Acharya, G; Elahy, M; Khachigian, LM; Li, Y; Xin, H, 2019) |
| "Flubendazole (FLU) is a widely used anthelmintic drug belonging to benzimidazole group." | 5.48 | Flubendazole induces mitotic catastrophe and apoptosis in melanoma cells. ( Čáňová, K; Rozkydalová, L; Rudolf, E; Vokurková, D, 2018) |
| "Mebendazole was prioritized to further characterize its mechanism of melanoma growth inhibition based on its favorable pharmacokinetic profile." | 5.35 | Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. ( Doudican, N; Orlow, SJ; Osman, I; Rodriguez, A, 2008) |
| " the apoptosis as well as autophagy and their related signaling in several stabilized cell lines as well as human explant melanoma cells treated with flubendazole (FLU)." | 3.96 | An analysis of mitotic catastrophe induced cell responses in melanoma cells exposed to flubendazole. ( Rudolf, E; Rudolf, K, 2020) |
| " We find that MBZ synergizes with the MEK inhibitor trametinib to inhibit growth of BRAFWT-NRASQ61K melanoma cells in culture and in xenografts, and markedly decreased MEK and ERK phosphorylation." | 3.85 | The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma. ( Abdussamad, M; Atkins, MB; Byers, SW; Calvert, V; Chen, YS; Dakshanamurthy, S; Fang, HB; Gaur, A; Petricoin, EF; Rosenthal, DS; Simbulan-Rosenthal, CM; Zapas, J; Zhou, H, 2017) |
| "Mebendazole (MBZ) was identified as a promising therapeutic on the basis of its ability to induce apoptosis in melanoma cell lines through a B-cell lymphoma 2 (BCL2)-dependent mechanism." | 3.79 | XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. ( Byron, SA; Doudican, NA; Orlow, SJ; Pollock, PM, 2013) |
| "In recent years, treatment of melanoma and a range of other deadly cancers has involved immunotherapy with programmed cell death protein-1 (PD-1)/PD-1 ligand (PD-L1) checkpoint blockade which has improved survival." | 1.51 | The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation. ( Acharya, G; Elahy, M; Khachigian, LM; Li, Y; Xin, H, 2019) |
| "Flubendazole (FLU) is a widely used anthelmintic drug belonging to benzimidazole group." | 1.48 | Flubendazole induces mitotic catastrophe and apoptosis in melanoma cells. ( Čáňová, K; Rozkydalová, L; Rudolf, E; Vokurková, D, 2018) |
| "Mebendazole was prioritized to further characterize its mechanism of melanoma growth inhibition based on its favorable pharmacokinetic profile." | 1.35 | Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. ( Doudican, N; Orlow, SJ; Osman, I; Rodriguez, A, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Rudolf, K | 1 |
| Rudolf, E | 2 |
| Čáňová, K | 1 |
| Rozkydalová, L | 1 |
| Vokurková, D | 1 |
| Li, Y | 1 |
| Acharya, G | 1 |
| Elahy, M | 1 |
| Xin, H | 1 |
| Khachigian, LM | 1 |
| Barrett, JE | 1 |
| Kim, FJ | 1 |
| Simbulan-Rosenthal, CM | 1 |
| Dakshanamurthy, S | 1 |
| Gaur, A | 1 |
| Chen, YS | 1 |
| Fang, HB | 1 |
| Abdussamad, M | 1 |
| Zhou, H | 1 |
| Zapas, J | 1 |
| Calvert, V | 1 |
| Petricoin, EF | 1 |
| Atkins, MB | 1 |
| Byers, SW | 1 |
| Rosenthal, DS | 1 |
| Doudican, N | 1 |
| Rodriguez, A | 1 |
| Osman, I | 1 |
| Orlow, SJ | 2 |
| Doudican, NA | 1 |
| Byron, SA | 1 |
| Pollock, PM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas[NCT01837862] | Phase 1/Phase 2 | 36 participants (Anticipated) | Interventional | 2013-10-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 other studies available for mebendazole and Malignant Melanoma
| Article | Year |
|---|---|
An analysis of mitotic catastrophe induced cell responses in melanoma cells exposed to flubendazole.
Topics: Aged; Antineoplastic Agents; Apoptosis; Autophagy; Cell Cycle; Cell Line, Tumor; Cytochromes c; Huma | 2020 |
Flubendazole induces mitotic catastrophe and apoptosis in melanoma cells.
Topics: Antinematodal Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Mebendazole; Melanoma | 2018 |
The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation.
Topics: Animals; Antinematodal Agents; Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Femal | 2019 |
The purpose of repurposing.
Topics: Anthelmintics; Humans; Mebendazole; Melanoma; Pyridones; Pyrimidinones | 2017 |
The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma.
Topics: Animals; Antinematodal Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cel | 2017 |
Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Benzimidazoles; Cell Line, Tumor; Cell Proliferation | 2008 |
XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts.
Topics: Animals; Apoptosis; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Femal | 2013 |